About this Journal Submit a Manuscript Table of Contents
Arthritis
Volume 2013 (2013), Article ID 514914, 4 pages
http://dx.doi.org/10.1155/2013/514914
Research Article

No Association between FCγR3B Copy Number Variation and Susceptibility to Biopsy-Proven Giant Cell Arteritis

1Rheumatology Department, The Queen Elizabeth Hospital, Woodville South, SA 5011, Australia
2The Health Observatory, Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
3Discipline of Medicine, The University of Adelaide, Adelaide, SA 5005, Australia
4Centre for Eye Research, Royal Victorian Eye and Ear Hospital, University of Melbourne, East Melbourne, VIC 3002, Australia
5Lions Institute, University of Western Australia, Nedlands, WA 6009, Australia

Received 26 June 2013; Accepted 21 July 2013

Academic Editor: Bruce M. Rothschild

Copyright © 2013 Emma Dunstan et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. To determine the relationship between FCGR3B gene copy number variation (CNV) and biopsy proven giant cell arteritis (GCA). Methods. FCGR3B CNV was determined in 139 Australian biopsy proven GCA patients and 162 population matched controls, using a duplex qPCR assay and RNase P as the reference gene. Copy number was determined using Copy Caller software (v.1.0, Applied Biosystems, USA). CNV genotypes were classified into 3 groups (<2, 2, 3+) for analysis purposes, and analysis was performed using logistic regression. Results. All GCA patients had a positive temporal artery biopsy, and the most common presenting symptoms were visual disturbance and temporal headache. The mean age of patients at biopsy was 74 years (range 51–94) and 88/139 (63%) were female. The frequency of low (<2) FCGR3B copy number was comparable between GCA patients ( %) and controls ( %), as was the frequency of high (3+) FCGR3B copy number (15/130 (10.8%) in GCA patients versus 13/162 (8.0%) in controls). Overall there was no evidence that FCGR3B CNV frequencies differed between GCA patients and controls ( , , ). Conclusion. FCGR3B CNV is not associated with GCA; however, replicate studies are required.